Neuromedin B receptor antagonist suppresses tumor angiogenesis and tumor growth in vitro and in vivo

Highlights ► Neuromedin B (NMB) receptor antagonist PD168368 inhibits NMB-induced endothelial angiogenesis in vitro and in vivo . ► PD168368 reduces viability and xenograft tumor growth of human MDA-MB-231 breast cancer cells. ► PD168368 induces cell cycle arrest and apoptosis in MDA-MB-231 cells. ►...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer letters 2011-12, Vol.312 (1), p.117-127
Hauptverfasser:	Park, Hyun-Joo, Kim, Su-Ryun, Kim, Mi-Kyoung, Choi, Kyu-Sil, Jang, Hye-Ock, Yun, Il, Bae, Soo-Kyung, Bae, Moon-Kyoung
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Animals Breast cancer Breast cancer cells Breast Neoplasms - blood supply Breast Neoplasms - drug therapy Breast Neoplasms - pathology Cell cycle Cell growth Cell Growth Processes - drug effects Female Hematology, Oncology and Palliative Medicine Humans Indoles - pharmacology Kinases Male Mice Mice, Inbred C57BL Mice, Nude Neovascularization, Pathologic - drug therapy Neovascularization, Pathologic - pathology Neuromedin B receptor antagonist Pyridines - pharmacology Rats Rats, Sprague-Dawley Receptors, Bombesin - antagonists & inhibitors Receptors, Bombesin - metabolism Tumor growth Vascular endothelial cells Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights ► Neuromedin B (NMB) receptor antagonist PD168368 inhibits NMB-induced endothelial angiogenesis in vitro and in vivo . ► PD168368 reduces viability and xenograft tumor growth of human MDA-MB-231 breast cancer cells. ► PD168368 induces cell cycle arrest and apoptosis in MDA-MB-231 cells. ► PD168368 exerts antitumor activity through the inhibition of tumor growth and angiogenesis.
ISSN:	0304-3835 1872-7980
DOI:	10.1016/j.canlet.2011.08.014